{
    "clinical_study": {
        "@rank": "87264", 
        "arm_group": [
            {
                "arm_group_label": "XELOX-X", 
                "arm_group_type": "Experimental", 
                "description": "XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.\nX Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
            }, 
            {
                "arm_group_label": "XELOX", 
                "arm_group_type": "Active Comparator", 
                "description": "XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance."
            }
        ], 
        "brief_summary": {
            "textblock": "To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of\n      elderly advanced gastric cancer (AGC) by comparing it with that of XELOX regimen."
        }, 
        "brief_title": "XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "To investigate whether XELOX with capecitabine maintenance treatment as 1st line treatment\n      in the elderly advanced gastric cancer is as effective and safe as XELOX regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ages Eligible for Study: 65 Years or older\n\n          -  Genders Eligible for Study: Both\n\n          -  The Eastern Cooperative Oncology Group (ECOG) status \u2264 2\n\n          -  Histologically confirmed gastric adenocarcinoma(including LAUREN type).\n\n          -  Measurable disease(according to the Response Evaluation Criteria in Solid Tumors\n             (RECIST) criteria 1.1).\n\n          -  chemotherapy naive after recurrence or metastasis. Previous neo-adjuvant or adjuvant\n             treatment for gastric cancer, if applicable, more than 6 months.\n\n          -  Hb > 90g/L, neutrophil count > or = 1.5*10^9/L, platelet > or = 100*10^9/L, alanine\n             transaminase (ALT) and aspartate aminotransferase (AST) < or = 2.5 times upper limit\n             of nominal (ULN), alkaline phosphatase (ALP) < or = 2.5 times ULN, total bilirubin\n             (TBIL) < 1.5 times ULN, serum albumin level > or = 30g/L, serum creatinine < 1 times\n             ULN.\n\n          -  No serious concomitant diseases which could lead to death within 5 years. At least 5\n             years from the last Biological/Immunotherapy/Hormone treatment for Malignancy\n             excluding gastric cancer.\n\n          -  Able to accept oral medication\n\n          -  Compliance with protocol\n\n        Exclusion Criteria:\n\n          -  Had received cytotoxic chemotherapy, radiotherapy or immunotherapy for this gastric\n             cancer, excluding Corticosteroids.\n\n          -  Other previous malignancy within 5 year, except curative skin cancer or carcinoma in\n             situ of uterine cervix.\n\n          -  Uncontrolled epilepsy, central nervous system disorders, or a history of mental\n             disorders.\n\n          -  clinically significant(i.e. active)cardiac disease e.g. symptomatic coronary artery\n             disease, New York Heart Association (NYHA) II or more serious congestive heart\n             failure or severe requiring medication intervention arrhythmia, or history of\n             myocardial infarction within the last 12 months.\n\n          -  Upper gastrointestinal obstruction or physiological dysfunction or suffering from\n             malabsorption syndrome, which could affect the absorption of capecitabine.\n\n          -  Organ transplantation requires immunosuppressive treatment.\n\n          -  Severe uncontrolled recurrent infections, or Other serious uncontrolled concomitant\n             diseases.\n\n          -  Moderate or severe renal impairment(creatinine clearance (CCr) = or < 50 ml/min), or\n             serum creatinine > ULN.\n\n          -  Known enzyme deficiency of dihydropyrimidine dehydrogenase(DPD).\n\n          -  Allergy to Oxaliplatin or any study medication ingredients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798251", 
            "org_study_id": "CGOG20120101009"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "XELOX-X", 
                    "XELOX"
                ], 
                "description": "Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "L-OHP"
            }, 
            {
                "arm_group_label": [
                    "XELOX-X", 
                    "XELOX"
                ], 
                "description": "capecitabine 850mg/m2 bid, d1-14, every 3 weeks", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "XELODA"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Elderly Gastric Cancer", 
            "Capecitabine Maintenance"
        ], 
        "lastchanged_date": "May 3, 2013", 
        "location": {
            "contact": {
                "email": "bai_yuxian@126.com", 
                "last_name": "Yuxian BAI, PhD", 
                "phone": "86 451 86298265"
            }, 
            "contact_backup": {
                "email": "doctorsui2003@126.com", 
                "last_name": "Hong SUI, PhD", 
                "phone": "86 13936592698"
            }, 
            "facility": {
                "address": {
                    "city": "Harbin", 
                    "country": "China", 
                    "state": "Heilongjiang", 
                    "zip": "150000"
                }, 
                "name": "The tumor hospital of Harbin medical university"
            }, 
            "investigator": [
                {
                    "last_name": "Yuxian BAI, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Hong SUI, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Single Center Phase II Study Comparing XELOX With Capecitabine Maintenance or XELOX Treatment in Elderly Metastatic Adenocarcinoma of Stomach", 
        "other_outcome": [
            {
                "measure": "health-related quality of life (HRQOL)", 
                "safety_issue": "Yes", 
                "time_frame": "evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage"
            }, 
            {
                "description": "quantitative real-time reverse transcriptase polymerase chain reaction (PCR) assays were performed to determine ERCC1 mRNA expression in tumor tissue.", 
                "measure": "excision repair cross-complementing 1(ERCC1) expression", 
                "safety_issue": "No", 
                "time_frame": "assays messager ribonucleic acid (mRNA) of ERCC1 expression in tumor tissue after randomization and before the first treatment"
            }, 
            {
                "description": "Genomic Deoxyribonucleic acid (DNA) is extracted from tumor tissue, direct sequencing technique is used to test K-ras gene type(mutation or wild).", 
                "measure": "K-ras gene type", 
                "safety_issue": "No", 
                "time_frame": "assess after randomization and before the first treatment"
            }
        ], 
        "overall_contact": {
            "email": "bai_yuxian@126.com", 
            "last_name": "Yuxian BAI, PhD", 
            "phone": "86 451 86298265"
        }, 
        "overall_contact_backup": {
            "email": "doctorsui2003@126.com", 
            "last_name": "Hong SUI, PhD", 
            "phone": "86 13936592698"
        }, 
        "overall_official": {
            "affiliation": "The tumor hospital of Harbin medical university", 
            "last_name": "Yuxian BAI, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798251"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Harbin Medical University", 
            "investigator_full_name": "BAI Yuxian", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "from the date of randomization until death from any cause or up to 1 year"
            }, 
            {
                "measure": "Response Rate (RR)", 
                "safety_issue": "No", 
                "time_frame": "evaluate every 6 weeks after the date of randomization until diease progress or up to 12 weeks"
            }, 
            {
                "measure": "adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "from date of randomization to 28 days after the last chemo dosage"
            }
        ], 
        "source": "Harbin Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Harbin Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}